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ABSTRACT
The novel nitrobenzoxadiazole (NBD) derivative MC3181 is endowed with 
remarkable therapeutic activity in mice bearing both sensitive and vemurafenib-
resistant human melanoma xenografts. Here, we report that subtoxic concentrations 
of this compound significantly reduced invasiveness of BRAF-V600D mutated WM115 
and WM266.4 melanoma cell lines derived from the primary lesion and related skin 
metastasis of the same patient, respectively. The strong antimetastatic activity of 
MC3181 was observed in both 2D monolayer cultures and 3D multicellular tumor 
spheroids, and confirmed in vivo by the significant decrease in the number of B16-F10 
melanoma lung metastases in drug-treated mice. Our data also show that MC3181 
affects the lactate production in the high glycolytic WM266.4 cell line. To unveil 
the MC3181 mechanism of action, we analyzed the ability of MC3181 to affect the 
degree of activation of different MAPK pathways, as well as the expression/activity 
levels of several proteins involved in angiogenesis, invasion, and survival (i.e. AP2, 
MCAM/MUC18, N-cadherin, VEGF and MMP-2). Our data disclosed both a decrease 
of the phospho-active form of JNK and an increased expression of the transcription 
factor AP2, events that occur in the very early phase of drug treatment and may be 
responsible of the antimetastatic effects of MC3181.
INTRODUCTION
Malignant melanoma progresses through a multi-
step process switching from dysplasia to radial growth 
phase, to invasive vertical growth phase, and subsequently 
to distant metastases. These switches implicate the breach 
of the basement membrane by neoplastic proliferating 
cells, their migration and stroma invasion to enter the 
vasculature, and finally their extravasation and adhesion 
in distant organs to form a secondary tumor [1–3]. Every 
phase of this complex scenario can be rate-limiting and 
offers potential target for therapy.
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Therapeutically, one of the most recent and 
promising approaches is immunotherapy that involves 
the use of immune checkpoint inhibitors enabling the 
interruption of T-cell pathways responsible for immune 
down-regulation or tolerance, such as the anti-CTLA-4 
monoclonal antibody (mAb) ipilimumab, along with 
the anti-PD-1 mAbs pembrolizumab and nivolumab. 
Another important class of drugs is represented by low 
molecular weight compounds interfering with signaling 
pathways involved in the dysregulation of cell growth 
and proliferation; this is the case of vemurafenib and 
dabrafenib, which target mutated v-raf murine sarcoma 
viral oncogene homolog B1 (BRAF), the selective 
inhibitors of extracellular signal-regulated kinase 
(ERK), as well as trametinib and cobimetinib targeting 
mitogen-activated protein kinase (MAPK)/ERK Kinase 
(MEK) proteins [4]. While these strategies provide a 
potential initial clinical benefit, they delay but not prevent 
patient mortality due to the ability of tumor to rapidly 
acquire resistance to drugs and/or to activate alternative 
proliferation pathways.
In contrast with current clinical trials targeting 
multiple signaling pathways involved in cell proliferation, 
we recently reported that the nitrobenzoxadiazole 
derivatives (NBDs) NBDHEX [6-((7-nitrobenzo[c]
[1,2,5]oxadiazol-4-yl)thio)hexan-1-ol] and its more water-
soluble analogue, MC3181 [2-(2-(2-((7-nitrobenzo[c]
[1,2,5]oxadiazol-4-yl)thio)ethoxy)ethoxy)ethanol], exert 
a potent antitumor activity through the activation of 
different MAPK pathways. These compounds represent a 
new class of antitumor agents exhibiting an outstanding 
therapeutic activity together with an extremely non-toxic 
profile in human cutaneous melanoma mouse xenografts. 
NBDHEX and MC3181 inhibit glutathione transferase 
P1-1 (GSTP1-1), and disrupt the GSTP1-1/JNK1 and 
GSTP1-1/TRAF2 complexes, thereby causing prolonged 
tumor cell cycle arrest and apoptosis. Therefore, these 
drugs may constitute a new effective strategy for the 
treatment of BRAF-mutated human melanomas, capable 
of overcoming the resistance to vemurafenib [5, 6].
On this ground, we were prompted to test the 
antimetastatic properties of the more soluble NBD 
derivative, MC3181, against melanoma cells lines derived 
from the primary lesion (WM115) and a skin metastasis 
(WM266.4) of a single patient harboring a BRAF-V600D 
mutation.
Our data revealed that subcytotoxic doses of 
MC3181 exert a strong antimetastatic activity in vitro. 
To understand the mechanism(s) underling this effect, we 
measured the expression/activity levels of key proteins 
involved in melanoma cells migration and invasion, 
and focused on signaling pathways that modulate these 
proteins. Moreover, using the B16-F10 melanoma mouse 
model of metastasis, we demonstrated that the oral 
administration of MC3181 exerts a potent antimetastatic 
effect, significantly suppressing and/or delaying lung 
metastasis in the absence of detectable sign of toxicity. 
These data provide evidence to further support the 
potential of MC3181 as a novel therapeutic to treat 
metastatic melanoma.
RESULTS
Antiproliferative activity of MC3181 and 
NBDHEX on WM115 and WM266.4 2D 
monolayer cultures and 3D multicellular tumor 
spheroids
The antitumor efficacy of MC3181 was tested in 
vitro on 2D WM115 and WM266.4 human melanoma cell 
cultures, and compared with NBDHEX, temozolomide 
(TMZ) and vemurafenib (VMF). The concentration–
response profiles (Supplementary Figure 1) fulfill the 
IC50 values reported in Table 1. Of note, the IC50 values 
calculated for MC3181 are in the low micromolar range 
(1.0–1.3 μM), and close to those obtained for both 
NBDHEX and vemurafenib (VMF), whereas TMZ is at 
least 600 times less effective.
Next, we decided to evaluate the effect of MC3181 
and its parent drug, NBDHEX, on 3D multicellular 
tumor spheroids, which are more precise in mimicking 
the complex organization of tumor tissue in vivo [7]. 
Spheroids were treated with graded concentrations of 
MC3181 (Figure 1b and 1d) or NBDHEX (Figure 1c and 
1e), and IC50 values were obtained by analyzing both cell 
viability (MTS) and growth rate. A schematic diagram 
for treatment schedule and analysis (cell imaging and 
viability assay) is shown in Figure 1a. We noticed that 
WM266.4 spheroids grew faster increasing their volume 
25 times at the end of the experiment (day 17, Figure 1d 
and 1e), whilst the WM115 counterparts augmented only 
8 times (Figure 1b and 1c). The IC50 values of MC3181 
on WM266.4 spheroids were in the low micromolar range 
(0.5–7.7 μM, Table 2), comparable at both 48 hours and 
17 days, and similar to those obtained with NBDHEX. 
In contrast, 48 hours treatment with both MC3181 and 
NBDHEX caused flaking of WM115 spheroids and 
formation of poorly defined contours that did not allow 
an accurate measurement of spheroids’ diameter (data 
not shown). Additionally, after 17 days of treatment, the 
spheroids’ viability dropped more slowly compared to the 
spheroids’ volume, resulting in loss of linear relationship 
between viability and cell number (Table 2). A similar 
event has been already reported and explained by the 
occurrence of cell cycle arrest [8].
Effect of low concentrations of MC3181 on cell 
proliferation and cell cycle
Since MC3181 and NBDHEX showed comparable 
activity in both WM115 and WM266.4 cells, we focused 
on the antimetastatic efficacy of the more water soluble 
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NBD derivative, namely MC3181. We investigated 
three different concentrations of MC3181 for each cell 
line: WM115 and WM266.4 cells were treated with 
MC3181 concentrations of 1.3 and 1.0 μM respectively 
(corresponding to their IC50 values), 0.26 and 0.20 μM 
respectively (corresponding to 1/5 of their IC50 values) and 
0.05 and 0.04 μM respectively (corresponding to 1/25 of 
their IC50 values).
We analyzed cell proliferation and cell cycle at 
different time points after the addition of MC3181. A 
decrease in the WM115 growth rate was observed after 
24 hours incubation with both 0.26 and 1.3 μM MC3181 
(Supplementary Figure 2a), which corresponds to a 
significant arrest in the G2/M phase of the cell cycle 
(Supplementary Figure 2b). In contrast, WM266.4 
showed only a slight decrease of cell proliferation after 48 
hours treatment with the highest MC3181 dose (1.0 μM) 
(Supplementary Figure 2c). In accordance, the WM266.4 
cell cycle was only slightly affected by treatment with 1.0 
μM MC3181 (Supplementary Figure 2d).
MC3181 treatment affects the adhesion 
properties of both WM115 and WM266.4 cells
The successful dissemination of tumor cells and the 
formation of new tumor foci require cancer cells adhesion 
and detachment from components of the extracellular 
matrix (ECM) and basement membrane (BM). Therefore, 
we analyzed the effect of MC3181 on the adhesion 
properties of WM115 and WM266.4 cells to different 
ECM components, i.e. type I collagen, Matrigel and 
gelatin [9, 10].
The primary tumor-derived WM115 cells showed 
poor basal adhesion on both gelatin and Matrigel 
(Figure 2b and 2c). The treatment with 0.26-1.3 μM 
MC3181 reduced to approximately 50% their adhesion 
to collagen (Figure 2a), whilst a concentration-dependent 
effect was observed on gelatin (Figure 2b), reaching an 
adhesion inhibition of 84% at 1.3 μM MC3181. This drug 
concentration was also able to abolish (96%) the adhesion 
of WM115 on Matrigel (Figure 2c).
The skin metastasis-derived WM266.4 cells showed 
excellent adhesion properties on all the substrates tested 
(Figure 2d-2f). However, the sensitivity to MC3181 
was clearly lower than that of WM115. Indeed, 0.04 μM 
MC3181 was sufficient to induce 40% reduction of cell 
adhesion to collagen (Figure 2d), but a significant effect 
(80% inhibition) on gelatin adhesion was evident only 
with 1.0 μM MC3181 (Figure 2e). Finally, MC3181 did 
not show any significant inhibitory effect on tumor cell 
adhesion to Matrigel (Figure 2f).
MC3181 inhibits invasion of human melanoma 
cells in vitro
Another aspect of tumor progression is the ability 
of tumor cells to invade basement membranes and 
connective tissue leading to the possible formation of 
distant metastases. We investigated the migratory and 
invasive potential of both primary tumor (WM115) and 
metastasis-derived (WM266.4) melanoma cells after 48 
hours treatment with MC3181. This compound efficiently 
suppressed invasion in both cell lines, without any effect 
on their migration (Figure 3a, 3b, 3f and 3g). Of note, a 
concentration of MC3181 corresponding to 1/25 of its IC50 
value (0.04 μM) was capable of inducing 75% reduction of 
WM266.4 invasion index (Figure 3h), while an equiactive 
concentration of MC3181 (0.05 μM) reduced the invasion 
index of WM115 by approximately 30% (Figure 3c). 
However, 60% inhibition of WM115 invasion index was 
obtained with 0.26 and 1.3 μM. Further, we evaluated 
the antimetastatic properties of MC3181 in a third tumor 
cell line, namely the BRAF-V600E-mutated SK-MEL-5 
human melanoma cell line, which has been established 
from an axillary lymph node metastasis. Based on the 
finding that in the SRB assay MC3181 exhibited an IC50 
value of 1.6 ± 0.1 μM towards SK-MEL-5 cells (data not 
shown), invasion/migration assays were carried out using 
the following drug concentrations: 1.60 μM (i.e., the IC50); 
0.32 μM (i.e., 1/5 of IC50); and 0.06 μM (i.e., 1/25 of the 
IC50) (Supplementary Figure 3). The invasive potential 
of SK-MEL-5 cells was reduced by approximately 30% 
by 0.32 μM MC3181 whereas, a 60% inhibition was 
recorded at a drug concentration of 1.6 μM. Furthermore, 
MC3181 significantly depressed migration of SK-MEL-5 
cells (Supplementary Figure 3a and 3b). Of note, a 50% 
reduction of cell migration was achieved with 0.32 and 1.6 
μM MC3181. Since the drug inhibited both SK-MEL-5 
cell invasion and migration, no change of the invasion 
index occurred (Supplementary Figure 3c).
Table 1: Evaluation of the antiproliferative (SRB assay) effects of MC3181, NBDHEX, VMF and TMZ on WM115 
and WM266.4 2D monolayer cultures
Cell line
IC50 ± SD (μM)
MC3181 NBDHEX VMF TMZ
WM115 1.28 ± 0.02 1.99 ± 0.01 2.47 ± 0.19 1196 ± 103
WM266.4 1.07 ± 0.04 0.94 ± 0.04 0.89 ± 0.01 800 ± 5
Oncotarget15523www.impactjournals.com/oncotarget
Figure 1: MC3181 and NBDHEX concentration-dependent inhibition of tumor spheroid growth. a. Schematic illustration of 
tumor spheroid growth kinetics and compound treatment procedures. Spheroids were treated with drug or drug vehicle 4 days after cell plating 
(day 0); 50% medium replenishment was performed on days 2, 4, 6, 10 and 14. b-c. WM115 and d-e. WM266.4 spheroids treated with graded 
concentrations of MC3181 (b and d) or NBDHEX (c and e). Control spheroids were treated with vehicle. Spheroid growth kinetics (left) was 
evaluated by phase contrast imaging at day 2, 6, 10, 14 and 17, whereas the concentration-response curves relative to the MTS assays and 
spheroid volume analysis were obtained after 48 hours (center) and 17 days (right) of drug treatment. Phase contrast images (10X magnification, 
3X digital magnification) correspond to 17 days treated spheroids. Scale bar: 100 μm. Values are means ± SD (n = 12).
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MC3181 treatment reduces MMP-2 intracellular 
activity
We next examined MMP-2 activity in WM115 and 
WM266.4 melanoma cells by gelatin zymography (Figure 
3d, 3e, 3i and 3l). Densitometric analysis showed that 
treatment of both cell lines with equiactive concentrations 
of MC3181 induced a reduction of the MMP-2 activity 
in a concentration-dependent manner. In particular, a 
significant inhibition of MMP-2 proteolytic activity was 
observed in WM115 and WM266.4 cells treated with a 
concentration of MC3181 corresponding to the IC50 value 
in these cell lines (i.e., 1.3 and 1.0 μM, respectively) 
(Figure 3e and 3l).
MC3181 affects invadopodia formation in 
WM115 and WM266.4 melanoma cell lines
The strong effect of MC3181 prompted us to 
investigate the possible effect of the drug on the formation 
of invadopodia, protrusions emanating from the surface 
of cells and characterized by a high proteolitic activity 
towards the ECM. We examined the ability of WM115 
and WM266.4 cells to degrade fluorescein-gelatin by 
observing the loss of fluorescence of the labeled gelatin 
and its correspondence with phalloidin structure, which 
identifies invadopodia puncta (Figure 4a and 4d). In 
addition, the presence of invadopodia was confirmed 
by measuring the fluorescence intensity of TRITC-
phalloidin (red line) and fluorescein-gelatin (green line) 
along an arbitrary line that crossed through neighboring 
invadopodia structures. Figures 4b for WM115 and 
4e for WM266.4 show a drastic decrease of the green 
fluorescence intensity in correspondence with an increase 
in the red fluorescence intensity of TRITC-phalloidin. 
Confocal microscopy analysis revealed a significant 
decrease in the number of cells with active invadopodia 
following treatment with concentrations of MC3181 
corresponding to 1/5 and 1/25 of its IC50 value in these cell 
lines (Figure 4c and 4f). Moreover, the highest MC3181 
concentrations (i.e., 1.3 and 1.0 μM for WM115 and 
WM266.4, respectively) completely inhibited adhesion 
of the cells to the fluorescein-gelatin layer. Under these 
conditions, it was not possible to estimate the percentage 
of cells with active invadopodia.
Effects of MC3181 treatment on intracellular 
metabolome of WM115 and WM266.4 melanoma 
cells
A comprehensive analysis of the effects of 
intracellular metabolome was carried out by quantitative 
1H-NMR spectroscopy on WM115 and WM266.4 cells 
following MC3181 treatment for 48 hours.
As shown in Supplementary Figure 4, we found a 
progressive decrease in the intracellular levels of lactate 
in the high glycolytic WM266.4 cells, while we did not 
found other metabolic changes in the same cells (see 
Supplementary Tables 1A and 1B). No evident effects on 
metabolome were found in WM115 cells treated at both 
low and high concentrations of MC3181.
Analysis of the effect of MC3181 treatment 
on the mRNA expression of a panel of genes 
involved in melanoma progression and 
metastatization
Qualitative RT-PCR was carried out to characterize 
WM115 and WM266.4 cell lines for the expression of 
a panel of genes, including the pro-angiogenic factors 
vascular endothelial growth factor (VEGF) and the basic 
fibroblast growth factor (FGF2); the matrix-metallo-
Table 2: Evaluation of the cytotoxic (MTS assay) and antiproliferative (volume analysis) effects of MC3181 and 
NBDHEX on WM115 and WM266.4 3D multicellular tumor spheroids
IC50 ± SD (μM)
WM115
48 hours 17 Days
Volume MTS Volume MTS
MC3181 n.d. 3.22 ± 0.19 0.53 ± 0.04 2.19 ± 0.15
NBDHEX n.d. 1.44 ± 0.08 0.37 ± 0.09 6.27 ± 0.94
WM266.4
48 hours 17 Days
Volume MTS Volume MTS
MC3181 1.67 ± 0.26 7.67 ± 1.00 1.10 ± 0.23 2.41 ± 0.40
NBDHEX 2.84 ± 0.19 2.44 ± 0.43 1.22 ± 0.33 3.60 ± 0.51
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Figure 2: Effect of MC3181 on the adhesion of human melanoma cells to different ECM components. WM115 cells and 
WM266.4 cells (3x105/ml) were applied to individual coated wells with 200 μl of a, d. collagen (7.5 μg/ml), b, e. gelatin (0.1%) or c, f. 
Matrigel (0.2 mg/ml), in the absence and in the presence of increasing MC3181 concentrations, and incubated for 30 minutes at 37°C in 
5% CO2. Cells were then fixed and colored with crystal violet. Images (20X magnification, 3X digital magnification) were obtained by 
phase contrast microscopy. The absorbance values of wells were measured at 580 nm after dissolving crystal violet with 100% methanol. 
The results were expressed as the mean percentage of cell adhesion ± SD versus control, repeated in triplicate; *P < 0.05, **P < 0.005 and 
*** P < 0.0005 vs control.
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Figure 3: MC3181 blocks WM115 and WM266.4 melanoma cells invasion and inhibits MMP2 activity. Cell lines were 
assayed for in vitro invasion and migration using Boyden chamber without coating (migration) or coated with 5 μg of Matrigel. After 
48 hours of treatment with graded MC3181 concentrations, migrated and invaded cells per field were stained with crystal violet and 
counted. Representative phase contrast images (10X magnification, 3X digital magnification) of a. WM115 and f. WM266.4 are shown.
Migrated/Invaded b. WM115 and g. WM266.4 cells. The invasion index of c. WM115 and h. WM266.4 cells was calculated as the invasion 
percentage of treated cells divided by the invasion percentage of non-treated cells (see equations 2 and 3 in “Materials and Methods” 
section). Intracellular MMP-2 activity was measured by gelatin zymography assay on d. WM115 and i. WM266.4 cells treated with graded 
MC3181 concentrations for up to 48 hours. ImageJ quantification of 3 independent experiments of gelatin zymography performed on e. 
WM115 and l. WM266.4 cells. The control has been settled as the 100%, and results were expressed as the mean percentage of MMP-2 
activity ± SD vs control. **P < 0.005 and ***P < 0.0005 vs control.
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proteinases 2 and 9 (MMP-2 and MMP-9); the cell-cell 
adhesion molecules E-cadherin (CDH1), N-cadherin 
(CDH2), Ve-cadherin (CDH5), and both the long and short 
isoforms of the endothelial antigen MCAM/MUC18 [11]. 
To validate our expression panel, we used two melanoma 
cell lines as positive control (M10 and M14) and β2-
microglobulin as housekeeping.
RT-PCR documented mRNA expression in all the 
melanoma cell lines analyzed (WM115, WM266.4, and 
the positive controls M10 and M14) for VEGF, FGF2, 
CDH2, CDH5, MMP-2, MMP-9, and the two isoforms 
of MCAM/MUC18. The mRNA expression levels of all 
the genes tested in WM115 and WM266.4 cell lines are 
shown in Figure 5a, and a representative gel is reported 
in Supplementary Figure 5. Afterwards, we analyzed 
the mRNA expression of these genes following 
treatment with equiactive concentrations of MC3181 
(corresponding to its IC50 value, 1/5 and 1/25 of its IC50 
value in these cell lines). CDH5, VEGF, FGF2, MMP-
2, MMP-9 and both the MCAM/MUC 18 Long and 
Short isoforms mRNA were still present at 24 hours in 
WM115 cells, while they drastically decreased at 48 
hours after treatment with all the MC3181 concentrations 
tested (Figure 5a, left). Interestingly, 9 hours of drug 
exposure were sufficient to induce a drastic decrease 
of the CDH2 mRNA (Figure 5a, left). Conversely, a 
strong reduction of mRNA expression of all genes 
could be observed in WM266.4 cells after 48 hours of 
Figure 4: Invadopodia matrix degradation activity. WM115 and WM266.4 cells were seeded on Fluorescein-Gelatin coated 
chamber slides for 5 hours, and then fixed and stained for TRITC-Phalloidin. a. WM115 and d. WM266.4 representative confocal images 
showing invadopodia as focal cytoplasmic concentrations of Phalloidin that overlap with areas of gelatin clearing (dark holes in the matrix) 
within the merged image, as indicated by arrows. Fluorescein-Gelatin images were pseudocolored in gray. Images were acquired with 
a 40X magnification oil immersion objective and a digital magnification 3X is shown. Scale bar = 10 μm. b. WM115 and e. WM266.4 
representative fluorescence intensity plot showing co-localization of TRITC-Phalloidin (red line) and gelatin degradation (green line). 
Fluorescence intensity was measured at each image pixel along an arbitrary line that crossed through an invadopodia structure. Percentage 
of c. WM115 and f. WM266.4 cells with active invadopodia was obtained by counting approximately 100 cells in 3 fields. Data shown are 
means ± SD of three independent experiments. *P < 0.05 and **P < 0.005 vs control.
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Figure 5: RT-PCR analysis of the mRNA expression of cancer progression related genes. a. Total RNA from untreated and 
MC3181-treated cells was extracted, reverse-transcribed, amplified by PCR, and submitted to electrophoresis on a 1.8% agarose gel (see 
“Materials and Methods” section). The graphs show the relative intensity of the PCR products vs β2-microglobulin, obtained by the ImageJ 
analysis software: -■-ctrl; -◊- 0.05 and 0.04 μM MC3181 (WM115 and WM266.4, respectively); -●- 0.26 and 0.20 μM MC3181 (WM115 
and WM266.4, respectively) and -∆- 1.3 and 1.0 μM MC3181 (WM115 and WM266.4, respectively). b. Relative intensity of the PCR 
products from WM266.4 cells treated for 48 hours with equiactive concentrations of MC3181 and VMF (1.0 μM vs 0.9 μM, respectively).
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treatment only with the highest concentration (1.0 μM) of 
MC3181 (Figure 5a, right). We did not detect the presence 
of CDH1 mRNA in both WM115 and WM266.4 cell lines, 
either before or after MC3181 treatment (data not shown).
Finally, we decided to perform a preliminary 
comparison of the efficacy of equiactive concentrations 
of MC3181 and VMF, corresponding to their IC50 
values (1.0 and 0.9 μM, respectively), on the mRNA 
expression. Interestingly, we found that MC3181 treatment 
outperformed VMF in the suppression of the genes 
analyzed after 48 hours, with the only exception of CDH5 
(Figure 5b).
MC3181 inhibits WM266.4 3D-multicellular 
tumor spheroid invasion into collagen type I
Tumor invasion was further analyzed in WM115 and 
WM266.4 cells grown as 3D-multicellular tumor spheroids 
and embedded in type I collagen. Under these experimental 
conditions, spheroids formed by WM115 cells were not 
able to invade the collagen matrix, and therefore subsequent 
experiments were performed only on WM266.4 cells. Also 
in this case, the compound was able to significantly reduce 
cells invasion into collagen, in a dose dependent manner 
(Figure 6). Twenty-four hour treatment with 0.04, 0.20 and 
1.0 μM MC3181 reduced the distance invaded by WM266.4 
cells by about 40, 60 and 80%, respectively, compared 
to the control. The effect obtained with 0.20 and 1.0 μM 
MC3181 remained constant over the 48 hours incubation 
period, while spheroids treated with 0.04 μM MC3181 
showed a recovery of their invasive potential.
MC3181 down-regulates the phospho-activation 
of c-Jun N-terminal kinase (JNK) and p38
To gain insight about the molecular mechanisms, 
we analyzed the effect of MC3181 treatment on proteins 
involved in WM266.4 cell invasion. Since activation 
of the MAPK/ERK pathway is a frequent event in 
tumorigenesis, we investigated the activation level of 
Figure 6: MC3181 inhibits WM266.4 spheroids invasion into type I collagen. 3D melanoma spheroids were embedded in a 
collagen matrix and treated with 0.04, 0.20 and 1.0 μM MC3181. The distance invaded by WM266.4 cells was monitored by phase contrast 
imaging (10X magnification, 3X digital magnification), over a 48 hours incubation period. Scale bar: 100 μm. The graph shows the mean 
distance invaded by spheroids ± SD; sample number: n = 10 for every condition; *P < 0.05, **P < 0.005 and ***P < 0.0005 vs the respective 
time-matched control.
